Is it okay to delay the administration of sintilimab by 2 days?

It is generally acceptable to delay administration of sintilimab by two days, as this short delay usually does not significantly affect treatment efficacy. The dosing schedule of this drug allows some flexibility, and a brief postponement will not lead to a substantial drop in drug concentration in the body or markedly weaken immune activation. If severe discomfort or changes in medical condition occur during the delay, prompt medical consultation is recommended.

As a PD-1 inhibitor, sintilimab exerts its anti-tumor effects by continuously activating the body's immune system. Its therapeutic effect relies on sustained, long-term immune response rather than the immediate impact of a single dose. A short delay of two days will not interrupt the established immune activation state nor increase the risk of adverse reactions.

In clinical practice, short-term adjustments to the dosing schedule are permitted under physician guidance, taking into account individual patient factors such as adverse events or scheduling of medical tests. However, frequent or prolonged delays should be avoided to prevent reduced cumulative drug effects and potential interference with overall treatment progress. After any adjustment, it is important to promptly communicate with the doctor regarding the follow-up dosing plan.

During treatment, maintain regular作息 (daily routines), avoid staying up late, eat a balanced diet rich in high-quality protein and vitamins, engage in moderate, gentle exercise to strengthen physical health, maintain emotional stability, and strictly adhere to medical advice for regular follow-up examinations to ensure the treatment plan progresses smoothly.